Shots:

• Shionogi to receive $27.2M up front- $20.4M upon the achievement of a clinical milestone along with royalties on net sales of S-365598 (HIV integrase inhibitor) & will provide the development costs up to an annual maximum
• The collaboration will advance ViiV Healthcare's pipeline for HIV treatment. The therapy has the potential for use in ultra long-acting HIV regimens with dosing intervals of ≥3mos.
• The preliminary data showed that S-365598 has a high genetic barrier and a resistance profile that are distinct from dolutegravir and cabotegravir. Additionally- both companies plan to initiate human studies of S-365598 by 2023

  | Ref: ViiV | Image: Businesswire